BIG 2-98

Closed

BIG 2-98/IBCSG 20-98: Adjuvant Taxotere

BCT Study Chair:

Prue Francis

An intergroup phase III trial to evaluate the activity of docetaxel, given either sequentially or in combination with doxorubicin, followed by CMF, in comparison to doxorubicin alone or in combination with cyclophosphamide, followed by CMF, in the adjuvant treatment of node-positive breast cancer patients.

2282

INTERNATIONAL

Total number of trial

participants internationally

605

AUSTRALIA & NEW ZEALAND

Total number of trial participants

in Australia and New Zealand

40

INSTITUTIONS

Total number of participating institutions

in Australia and New Zealand

BIG 2-98 PUBLICATIONS

2022

Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer.

Loi S, Salgado R, Adams S, Pruneri G, Francis PA, Lacroix-Triki M, Joensuu H, Dieci MV, BAdve S, Demaria S, Gray R, Munzone E, Drubay D, Lemonnier J, Sotiriou C, Kellokumpu-Lehtinen PL, Vingiani A, Gray K, Andre F, Denkert C, Piccart M, Roblin E, Michiels S. npj Breast Cancer. 2022; 8(1):3. epub 11 January 2022; , https://doi.org/10.1038/s41523-021-00362-1, E-pub

2021

Heparanase: a potential marker of worse prognosis in estrogen receptor-positive breast cancer.

Zahavi T, Salmon-Divon M, Salgado R, Elkin M, Hermano E, Rubinstein AM, Francis PA, Di Leo A, Viale G, de Azambuja E, Ameye L, Sotiriou C, Salmon A, Kravchenko-Balasha N, Sonnenblick A. npj Breast Cancer. 2021; 767, E-pub

2020

Differential benefit of adjuvant docetaxel-based chemotherapy in patients with early breast cancer according to baseline body mass index.

Desmedt C, Fornili M, Clatot F, Demicheli R, De Bortoli D, Di Leo A, Viale G, de Azambuja E, Crown J, Francis PA, Sotiriou C, Piccart M, Biganzoli E. Journal of Clinical Oncology. 2020; 38(25):2883-2891, epub 20/05/20 https://doi.org/10.1200/JCO.19.01771, E-pub

2019

Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37,298 women with early breast cancer in 26 randomised trials.

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). The Lancet 2019; 393(10179):1440-1452 (epub 7/02/19), [http://dx.doi.org/10.1016/S0140-6736(18)33137-4], Journal

Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers.

Loi S, Drubay D, Adams S, Pruneri G, Francis PA, Lacroix-Triki M, Joensuu H, Dieci MV, Badve S, Demaria S, Gray R, Monzone E, Lemonnier J, Sotiriou C, Piccart MJ, Kellokumbu-Lehtinen P-L, Vingiani A, Gray K, Andre F, Kenkert C, Salgado R, Michiels S. Journal of Clinical Oncology. 2019; 37(7):559-569 (epub 16 January 2019; , https://doi.org/10.1200/JCO.18.01010), Journal

2018

Immune infiltration in invasive lobular breast cancer.

Desmedt C, Salgado R, Fornili M, Pruneri G, Van den Eynden G, Zoppoli G, Rothe F, Buisseret L, Garoud S, Willard-Gallo K, Brown D, Bareche Y, Rouas G, Galant C, Burtucci F, Loi S, Viale G, Di Leo A, Green AR, Ellis IO, Rakha EA, Larsimont D, Biganzoli E, Sotiriou C. Journal of the National Cancer Institute. 2018; 110(7):768-776, Journal

BIG 2-98